Novartis (NVS) has its share of troubles, but Barron's says fears about the company's outlook...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis (NVS) has its share of troubles, but Barron's says fears about the company's outlook may be overblown and shares are cheap, worth roughly what they were at the end of 2005 despite doubling its dividend and growing profits at double-digit rates. Even with looming patent expiries, Novartis boasts a diverse drug pipeline and shares could return 25-30% in the next two years.

Subscribe for full text news in your inbox